Pfizer may sell women’s health biz

Nov 01, 2018

Pfizer is considering the sale of its women’s health portfolio as the drugmaker looks to focus on developing treatments with higher growth potential, according to Bloomberg sources.

The drugmaker is privately working with financial advisers to gauge interest from potential buyers. The division has annual sales of roughly $1.2 billion, and sources expect that a sale could yield about $2 billion.

Pfizer recently reported worse-than-expected third quarter revenue and lowered its full-year sales forecast as it struggles to deal with generic competition, manufacturing issues and drug pricing pressure in the United States.

Pfizer has not commented on the potential women’s health sale.

Read the Bloomberg coverage

Don't miss your Daily Dose! Subscribe to the daily eNewsletter

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments